PRPH

Across TCGA pan-cancer cohorts, PRPH mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PRPH’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PRPH mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PRPH is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where PRPH tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRPH mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−2.437	<.001	12	view →
CCRCC	Male	III,IV	−1.859	<.001	12	view →
COAD	Male	III,IV	−2.326	<.001	11	view →
LUAD	Male	III,IV	−1.091	<.001	8	view →
LSCC	Female	All	−0.999	<.001	8	view →
OV	All	All	−3.099	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PRPH–HNSC

Open the HNSC breakdown →